Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PGD (Phosphogluconate Dehydrogenase) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PGD Recombinant Protein (Full Length) / Mutant High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PGD Products |
| Resistance Mutant | PGD Mutant Variants (Hotspot Mutations including rs11547610) Validated mutations for resistance mechanism studies. |
View PGD Products |
| Gene Delivery | PGD Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and CRISPR rescue. |
View PGD Products |
| Research Antibody | Anti-PGD Monoclonal Antibody High-specificity clone for ELISA, Western Blot, and IHC validation. |
View PGD Products |
| Validator | PGD siRNA Set For knockdown verification and specificity controls. |
View PGD Products |
| Related Target: G6PD | G6PD (Glucose-6-Phosphate Dehydrogenase) Rate-limiting upstream enzyme; compensatory pathway analysis and counter-screening. |
View G6PD Products |
| Related Target: TKT | TKT (Transketolase) Non-oxidative PPP node; synthetic lethality and combination therapy studies. |
View TKT Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzyme Kinetics & Inhibitor Screening | High-purity (>95%) active PGD; Sequence-verified catalytic domain; Consistent batch-to-batch NADPH production rates. |
| Paralog Selectivity (vs G6PD/IDH) | Human PGD, G6PD, and IDH1/2 recombinant proteins strictly verified by mass spec; >95% purity for counter-screening. |
| Resistance Mutation Analysis | Mutant protein panel covering reported resistance sites (e.g., rs11547610); Mass spec verified; Available for mechanistic studies. |
| Cross-species PK/PD Translation | Human / Mouse / Cyno ortholog proteins available with matched endotoxin specs (<1 EU/µg). |
| Target Engagement & Cell Model Validation | Validated PGD antibody and siRNA included; Lentivirus for stable knockdown rescue and overexpression experiments. |
Live PGD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The targeting of PGD within the oxidative pentose phosphate pathway (PPP) represents a critical metabolic vulnerability in rapidly proliferating cancer cells. The field is transitioning from academic validation to early drug discovery, with first-generation small molecule inhibitors advancing through preclinical optimization. Major players are shifting focus from broad anti-metabolic agents to selective PGD allosteric inhibitors capable of sparing G6PD activity to maintain redox homeostasis in normal tissues. Future R&D heavily targets synthetic lethality paradigms—combining PGD inhibition with ROS-inducing therapies or blocking both oxidative and non-oxidative PPP nodes to prevent metabolic compensation. Emerging biotech and academic consortia are leading the effort, and the next wave will involve combination regimens with chemotherapy, radiotherapy, or immune checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Allosteric & active-site binders | Solid Tumors (Breast, Lung, Melanoma), Hematological Malignancies | Enzymatic Activity Assay (Need high-purity active PGD protein with validated kinetic parameters) |
| Genetic & Epigenetic Targeting (siRNA/CRISPR) | Synthetic lethality combinations, knockdown validation | Hepatocellular Carcinoma, Breast, Lung, AML | Knockdown Validation & Rescue Assay (Need PGD siRNA and ORF lentivirus) |
| Combination & Metabolic Profiling | NADPH/6PG flux monitoring, drug resistance studies | Refractory Cancers, Drug-resistant Cancers | Resistance Mutant Panel & Pathway Analysis (Need mutant vs WT proteins and multi-target reagents) |
Key Resistance Mutations and Assay Needs
With the first PGD inhibitors entering preclinical development, resistance mutations are expected to emerge. The dbSNP variant rs11547610 and hotspots such as R298A, E361Q are key targets for resistance mechanism studies. TarMart provides validated mutant protein variants covering these sites for counter-screening and second-generation inhibitor development.